Navigation Links
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Date:4/26/2013

MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor.

The US-based study is an open-label, multicenter, single-arm clinical trial designed to assess the efficacy of MOR208 in patients suffering from relapsed or refractory B-ALL. Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208. In total, 30 patients are planned to be enrolled. More information on the trial can be found by searching for MOR208 at www.clinicaltrials.gov.

"Preclinical and early clinical studies of MOR208 have shown promising anti-tumor activity and supported this additional study in ALL as well as another study in Non Hodgkin's Lymphoma which is expected to start shortly," said Bassil Dahiyat , Ph.D., Chief Executive Officer of Xencor. "Xencor monoclonal antibody candidates continue to advance in clinical development and showcase the value of our XmAb® Fc technology."

MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition to the phase 2 trial in B-ALL MorphoSys is about to start a second Phase 2 trial in Non-Hodgkin's Lymphoma (NHL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and fifty thousand patients in the seven major markets each year. The target molecule CD19
'/>"/>

SOURCE Xencor
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. New monoclonal antibody developed that can target proteins inside cancer cells
3. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
4. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
5. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
6. Labor der Zukunft -- Tomorrows laboratory technology
7. The future of plant science - a technology perspective
8. The future of plant science a technology perspective
9. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
10. UF researchers look for ways to make an emerging technology safe for environment
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... YORK (August 21, 2013) Reproductive genetics researchers ... a multicenter prospective clinical study investigating the effects ... prenatally through microarray analysis. The goal of the ... variances previously not well reported in the medical ...
... July issue of the Journal of Spinal Cord Medicine ... Cord Injury." Guest Editor Rory Cooper, PhD, is a member ... FISA/PVA Endowed Chair and a Distinguished Professor of the Department ... Sciences, University of Pittsburgh. He is also the Center ...
... Amsterdam, NL, 21 August 2013 Metals such as ... processes. In recent years, studies have shown that these ... brains and some animal models of AD. Scientists are ... seen in AD or are indicative of other ongoing ...
Cached Biology News:Trial aims to advance prenatal diagnosis of genetic defects 2Trial aims to advance prenatal diagnosis of genetic defects 3Trial aims to advance prenatal diagnosis of genetic defects 4Journal of Spinal Cord Medicine publishes special issue on assistive technology 2Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD 2
(Date:4/1/2015)... April 01, 2015 The concept of “spot ... multi-billion dollar industry. Founder of Fasciology, Ashley Black, says that ... of fat, instead of having to wait for the whole ... that “ prior to fat cooling procedures, the only ... contouring, was liposuction, which is a highly invasive procedure.” It ...
(Date:3/31/2015)... Fla. , March 31, 2015  Biotest Pharmaceuticals ... is pleased to announce the addition of its newest ... Suite 205 Conway, Arkansas . The ... doors for business on March 26 th 2015 ... centers to eighteen. "This facility represents ...
(Date:3/31/2015)... , March 31, 2015  Sonoa Health, a health ... , has developed a world-first consumer health portal, Health&, ... prescriptions, wearable devices and more. Today, the ... as its CEO, who brings to the table more ... which has included working closely with the biggest names ...
(Date:3/31/2015)... , March 31, 2015  University of ... will deliver the plenary session address on Monday, ... Microwave Symposium (IMS) , kicking off a week of ... at the intersection of RF and microwave technologies with ... of Radios, Sensors and Circuits for the Skin," will ...
Breaking Biology Technology:Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3Health and Engineering Converge at the 2015 International Microwave Symposium 2Health and Engineering Converge at the 2015 International Microwave Symposium 3
... Oct. 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. ("SemBioSys") ... entered into a definitive agreement to acquire all ... Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and ... an initial 9.48 percent shareholding in Advitech, in ...
... BEIJING, Oct. 20, 2009 Monsanto Company and Huazhong ... the development of novel traits such as higher yield, ... and advance certain technologies developed by Professor Qifa Zhang,s ... "We,re excited to be working with a prominent research ...
... 20 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today financial ... reported third quarter revenue of $94.9 million, a 41.8% increase ... a 7.3% increase over the $88.5 million for the second ...
Cached Biology Technology:SemBioSys provides an update on Botaneco 2SemBioSys provides an update on Botaneco 3SemBioSys provides an update on Botaneco 4Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 2Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 3NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 12
...
... Plate is a 96-well ELISA-compatible plate (containing 12 ... Fiber Monoclonal Antibody is immobilized by a method ... recognizes the tail fiber protein of the T7 ... of 10 9 phage per well and ...
... The DNA Engine Dyad instrument is the ... Featuring MJ's world-class thermal performance, the ... display, as well as point-and-click navigation via ... Dyad can be easily and economically expanded ...
... Distributed exclusively by BioLegend, the Quansys ... for multiplex analysis of cytokines/chemokines for human, ... Cytokine Array is a fully quantitative ELISA-based ... been absorbed to each well of a ...
Biology Products: